923288-95-3

Usage

Uses

Used in Oncology:
Nilotinib hydrochloride anhydrous is used as an anticancer agent for the treatment of chronic myelogenous leukemia. It functions by inhibiting the activity of the BCR-ABL tyrosine kinase, which is a crucial driver of the uncontrolled cell growth observed in CML. This targeted approach helps to control the disease and improve patient outcomes.
Used in COVID-19 Research:
Nilotinib hydrochloride anhydrous is also used as a research product in the context of COVID-19. Its potential role in this area may involve modulating the immune response or targeting specific pathways relevant to the SARS-CoV-2 virus. As a COVID-19-related research product, it contributes to the ongoing efforts to understand and combat the pandemic.

Upstream product

• 641571-10-0 nilotinib 
• 641571-11-1 3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)aniline 
• 915711-42-1 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-aminobenzamide 
• 1449570-25-5 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-nitrobenzamide hydrochloride 
• 1345336-53-9 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-guanidinobenzamide 

Relevant academic research and scientific papers

Method for preparing nilotinib monohydrochloride dihydrate crystal form A

The invention provides a method for preparing nilotinib monohydrochloride dihydrate crystal form A. Specifically, the method provided by the invention comprises the following steps: (1) mixing nilotinib a free alkali as shown in a formula I, hydrochloric

CRYSTALLINE FORM OF NILOTINIB HYDROCHLORIDE, PROCESS FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME

The present invention relates to novel crystalline form of nilotinib hydrochloride, process for its preparation and pharmaceutical composition comprising the same.

KINASE INHIBITOR SALTS AND COMPOSITIONS THEREOF

The present invention relates to kinase inhibitor C8-C16 aliphatic sulfate salts and compositions thereof.

PROCESS FOR THE PREPARATION OF PURE NILOTINIB AND ITS SALT

Object of the present invention is a process for the preparation of the pharmaceutical active ingredient Nilotinib free base or Nilotinib dihydrochloride dihydrate by means of an improved crystallization procedure.

NOVEL SALTS OF NILOTINIB AND CRYSTALLINE FORMS THEREOF

The present invention provides novel salts of Nilotinib and crystalline forms thereof. Specific salt and crystalline forms thereof provided by the present invention include Nilotinib trihydrochloride dihydrate Form APO-VIII, Nilotinib gentisate Form APO-I, Nilotinib gentisate Form APO-II, Nilotinib digentisate Form APO-III, Nilotinb dibenzoate Form APO-I, Nilotinib dilevulinate Form APO-I, Nilotinib saccharinate monohydrate Form APO-I, Nilotinib saccharinate Form APO-II, Nilotinib diglycolate Form APO-I and Nilotinib glycerophosphate Form APO-I.

Novel nilotinib hydrochloride crystal form and preparation method and medical application thereof

The invention relates to a novel nilotinib hydrochloride crystal form and a preparation method and medical application thereof, in particular to a novel nilotinib hydrochloride crystal form with the structural formula shown as the formula (I) (please see

NOVEL POLYMORPHIC FORM X OF NILOTINIB DIHYDROCHLORIDE HYDRATE

The present invention relates to a novel polymorph of nilotinib hydrochloride(Form X), to processes for its preparation, to pharmaceutical compositions containing the same and to its use in medicine.

AN IMPROVED PROCESS FOR THE PREPARATION OF NILOTINIB AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF

The present invention relates to an improved process for the preparation of nilotinib and pharmaceutically acceptable salts thereof, with high purity and yields.

SOLID FORMS OF NILOTINIB HYDROCHLORIDE

Disclosed are solid forms of Nilotinib hydrochloride and methods of preparation of various crystalline solvates of Nilotinib HCl including benzyl alcohol, acetic acid, propylene glycol, and isopropanol. Nilotinib HCl is a tyrosine kinase inhibitor used for the treatment of drug resistant chronic myelogenous leukemia (CML).

PROCESS FOR THE PREPARATION OF NILOTINIB

The present invention relates a process for the preparation of a compound of formula (I): or a pharmaceutically acceptable salt thereof, which process comprises converting a compound of formula (IV): or a pharmaceutically acceptable salt thereof, into the compound of formula (I) or a pharmaceutically acceptable salt thereof.